These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 16721043)

  • 1. Sequence mutations and amplification of PIK3CA and AKT2 genes in purified ovarian serous neoplasms.
    Nakayama K; Nakayama N; Kurman RJ; Cope L; Pohl G; Samuels Y; Velculescu VE; Wang TL; Shih IeM
    Cancer Biol Ther; 2006 Jul; 5(7):779-85. PubMed ID: 16721043
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Amplicon profiles in ovarian serous carcinomas.
    Nakayama K; Nakayama N; Jinawath N; Salani R; Kurman RJ; Shih IeM; Wang TL
    Int J Cancer; 2007 Jun; 120(12):2613-7. PubMed ID: 17351921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. PIK3CA alterations in Middle Eastern ovarian cancers.
    Abubaker J; Bavi P; Al-Haqawi W; Jehan Z; Munkarah A; Uddin S; Al-Kuraya KS
    Mol Cancer; 2009 Jul; 8():51. PubMed ID: 19638206
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epithelial ovarian cancer: rationale for changing the one-fits-all standard treatment regimen to subtype-specific treatment.
    Despierre E; Yesilyurt BT; Lambrechts S; Johnson N; Verheijen R; van der Burg M; Casado A; Rustin G; Berns E; Leunen K; Amant F; Moerman P; Lambrechts D; Vergote I;
    Int J Gynecol Cancer; 2014 Mar; 24(3):468-77. PubMed ID: 24557434
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oncogenic PIK3CA gene mutations and HER2/neu gene amplifications determine the sensitivity of uterine serous carcinoma cell lines to GDC-0980, a selective inhibitor of Class I PI3 kinase and mTOR kinase (TORC1/2).
    English DP; Bellone S; Cocco E; Bortolomai I; Pecorelli S; Lopez S; Silasi DA; Schwartz PE; Rutherford T; Santin AD
    Am J Obstet Gynecol; 2013 Nov; 209(5):465.e1-9. PubMed ID: 23891627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Patterns of p53 mutations separate ovarian serous borderline tumors and low- and high-grade carcinomas and provide support for a new model of ovarian carcinogenesis: a mutational analysis with immunohistochemical correlation.
    Singer G; Stöhr R; Cope L; Dehari R; Hartmann A; Cao DF; Wang TL; Kurman RJ; Shih IeM
    Am J Surg Pathol; 2005 Feb; 29(2):218-24. PubMed ID: 15644779
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association of PI3 kinase signaling and chemoresistance in advanced ovarian cancer.
    Carden CP; Stewart A; Thavasu P; Kipps E; Pope L; Crespo M; Miranda S; Attard G; Garrett MD; Clarke PA; Workman P; de Bono JS; Gore M; Kaye SB; Banerji U
    Mol Cancer Ther; 2012 Jul; 11(7):1609-17. PubMed ID: 22556379
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low-grade serous carcinomas of the ovary contain very few point mutations.
    Jones S; Wang TL; Kurman RJ; Nakayama K; Velculescu VE; Vogelstein B; Kinzler KW; Papadopoulos N; Shih IeM
    J Pathol; 2012 Feb; 226(3):413-20. PubMed ID: 22102435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. High Frequency of
    Ishibashi T; Nakayama K; Razia S; Ishikawa M; Nakamura K; Yamashita H; Dey P; Iida K; Kurioka H; Nakayama S; Otsuki Y; Ishikawa N; Kyo S
    Diagnostics (Basel); 2019 Dec; 10(1):. PubMed ID: 31892193
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinicopathologic and biological analysis of PIK3CA mutation in ovarian clear cell carcinoma.
    Rahman M; Nakayama K; Rahman MT; Nakayama N; Ishikawa M; Katagiri A; Iida K; Nakayama S; Otsuki Y; Shih IeM; Miyazaki K
    Hum Pathol; 2012 Dec; 43(12):2197-206. PubMed ID: 22705003
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutations in FGFR3 and PIK3CA, singly or combined with RAS and AKT1, are associated with AKT but not with MAPK pathway activation in urothelial bladder cancer.
    Juanpere N; Agell L; Lorenzo M; de Muga S; López-Vilaró L; Murillo R; Mojal S; Serrano S; Lorente JA; Lloreta J; Hernández S
    Hum Pathol; 2012 Oct; 43(10):1573-82. PubMed ID: 22417847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Frequent activating mutations of PIK3CA in ovarian clear cell carcinoma.
    Kuo KT; Mao TL; Jones S; Veras E; Ayhan A; Wang TL; Glas R; Slamon D; Velculescu VE; Kuman RJ; Shih IeM
    Am J Pathol; 2009 May; 174(5):1597-601. PubMed ID: 19349352
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PPP2R1A mutation is a rare event in ovarian carcinoma across histological subtypes.
    Rahman M; Nakayama K; Rahman MT; Nakayama N; Katagiri H; Katagiri A; Ishibashi T; Ishikawa M; Iida K; Otsuki Y; Nakayama S; Miyazaki K
    Anticancer Res; 2013 Jan; 33(1):113-8. PubMed ID: 23267135
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mutational analysis of AKT1, AKT2 and AKT3 genes in common human carcinomas.
    Soung YH; Lee JW; Nam SW; Lee JY; Yoo NJ; Lee SH
    Oncology; 2006; 70(4):285-9. PubMed ID: 17047397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Alternate molecular genetic pathways in ovarian carcinomas of common histological types.
    Willner J; Wurz K; Allison KH; Galic V; Garcia RL; Goff BA; Swisher EM
    Hum Pathol; 2007 Apr; 38(4):607-13. PubMed ID: 17258789
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Spectrum of
    Chui MH; Chang JC; Zhang Y; Zehir A; Schram AM; Konner J; Drilon AE; Da Cruz Paula A; Weigelt B; Grisham RN
    JCO Precis Oncol; 2021; 5():. PubMed ID: 34568720
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Occurrence of low frequency PIK3CA and AKT2 mutations in gastric cancer.
    Zhang QY; Cheng WX; Li WM; Au W; Lu YY
    Mutat Res; 2014 Nov; 769():108-12. PubMed ID: 25771729
    [TBL] [Abstract][Full Text] [Related]  

  • 18. PIK3CA amplification associates with resistance to chemotherapy in ovarian cancer patients.
    Kolasa IK; Rembiszewska A; Felisiak A; Ziolkowska-Seta I; Murawska M; Moes J; Timorek A; Dansonka-Mieszkowska A; Kupryjanczyk J
    Cancer Biol Ther; 2009 Jan; 8(1):21-6. PubMed ID: 19029838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High prevalence of PIK3CA/AKT pathway mutations in papillary neoplasms of the breast.
    Troxell ML; Levine J; Beadling C; Warrick A; Dunlap J; Presnell A; Patterson J; Shukla A; Olson NR; Heinrich MC; Corless CL
    Mod Pathol; 2010 Jan; 23(1):27-37. PubMed ID: 19898424
    [TBL] [Abstract][Full Text] [Related]  

  • 20. BRAF
    Turashvili G; Grisham RN; Chiang S; DeLair DF; Park KJ; Soslow RA; Murali R
    Histopathology; 2018 Sep; 73(3):438-443. PubMed ID: 29770477
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.